Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy



Status:Completed
Conditions:Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:8/19/2017
Start Date:February 4, 2014
End Date:April 13, 2016

Use our guide to learn which trials are right for you!

A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)

The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh
muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).


Key Inclusion Criteria:

- Genetic diagnosis of SBMA with symptomatic muscle weakness

- Able to complete 2 minute timed walk

- Serum IGF-1 level less than or equal to 170 ng/mL

Key Exclusion Criteria:

- Medically treated diabetes mellitus or known history of hypoglycemia

- History of Bell's palsy

- Treatment with systemic steroids > 10 mg/day (or equivalent dose); androgens or
androgen reducing agents; systemic beta agonists; or other muscle anabolic drugs
within the previous 3 months

- History of cancer, other than non-melanomatous skin cancer

- Retinopathy

- Papilledema Other protocol defined inclusion/exclusion criteria may apply
We found this trial at
4
sites
Columbus, Ohio 43205
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Bethesda, Maryland 20892
Phone: 301-451-8146
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Copenhagen,
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials